| Literature DB >> 33763076 |
Joel Jihwan Hwang1, Yeri Alice Rim2, Yoojun Nam2, Ji Hyeon Ju2,3.
Abstract
Mesenchymal stem cell (MSC) therapies have been used as cell-based treatments for decades, owing to their anti-inflammatory, immunomodulatory, and regenerative properties. With high expectations, many ongoing clinical trials are investigating the safety and efficacy of MSC therapies to treat arthritic diseases. Studies on osteoarthritis (OA) have shown positive clinical outcomes, with improved joint function, pain level, and quality of life. In addition, few clinical MSC trials conducted on rheumatoid arthritis (RA) patients have also displayed some optimistic outlook. The largely positive outcomes in clinical trials without severe side effects establish MSCs as promising tools for arthritis treatment. However, further research is required to investigate its applicability in clinical settings. This review discusses the most recent advances in clinical studies on MSC therapies for OA and RA.Entities:
Keywords: cartilage; cell therapy; mesenchymal stem cell; osteoarthritis; rheumatoid arthritis
Year: 2021 PMID: 33763076 PMCID: PMC7982594 DOI: 10.3389/fimmu.2021.631291
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561